Thrombocytosis clinical trials
The registry lists 34 studies for Thrombocytosis across more than 10 countries. 8 are recruiting or about to start. 7 of them are mainly about Thrombocytosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its narrower condition Thrombocythemia, Essential too: 254 studies, 45 open.
Get an email when these change. Save the Thrombocytosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
M.D. Anderson Cancer Center (2) · Incyte Corporation (2) · Novartis Pharmaceuticals (2) · Azienda Ospedaliera Universitaria Integrata Verona (1) · Astex Pharmaceuticals, Inc. (1) · University Hospital, Angers (1) · Geron Corporation (1) · Sanjay Gandhi Postgraduate Institute of Medical Sciences (1)
What is being tested here
Drugs under test in Thrombocytosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Ropeginterferon alfa-2b | 1 | 1 | 3 |
| Ruxolitinib | 0 | 0 | 2 |
| Azacitidine | 0 | 0 | 1 |
| Pevonedistat | 0 | 0 | 1 |
| Venetoclax | 0 | 0 | 1 |
| Imetelstat | 0 | 1 | 1 |
| Itacitinib | 0 | 0 | 1 |
| Sonidegib | 0 | 0 | 1 |
| Pomalidomide | 0 | 0 | 1 |
| Decitabine | 0 | 0 | 1 |
Drug classes tested here JAK inhibitors 4 · Tyrosine kinase inhibitors (TKIs) 4 · Antimetabolites 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4
- Dec 2026A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Jan 2027Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia · M.D. Anderson Cancer Center
- Apr 2027Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) · University Hospital, Angers
- Apr 2027Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs · Cellenkos, Inc.
Who these studies take
Of the 5 Thrombocytosis studies recruiting now, 4 (80%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (20%) | 1 (20%) |
| 18 | 5 (100%) | 5 (100%) |
| 30 | 5 (100%) | 5 (100%) |
| 40 | 5 (100%) | 5 (100%) |
| 50 | 5 (100%) | 5 (100%) |
| 65 | 5 (100%) | 5 (100%) |
| 75 | 5 (100%) | 5 (100%) |
| 85 | 5 (100%) | 5 (100%) |
Across all 34 studies, recruiting or not: 15% stop at 75 or younger and 15% at 65; 15% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 34 of 34. search them.
- Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic LeukemiaNot yet recruitingNCT07468916Phase 21 country
- Leading in MPNs Beyond Ruxolitinib in Combo With T-RegsRecruitingNCT05423691Phase 11 country
- Therapeutic RSK1 Targeting in Myeloid MalignanciesRecruitingNCT07379125Phase 11 country
- A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesRecruitingNCT072037685 countries
- Molecular Biology of Polycythemia and ThrombocytosisRecruitingNCT007225271 country
- Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)RecruitingNCT04942080Not applicable1 country
- Platelet Transfusion in Critically Ill Patients With ThrombocytopeniaNot yet recruitingNCT06599385Phase 3
- Aetiology And Outcome Of Children With Thrombocytosis Admitted to Assiut University Children HospitalNot yet recruitingNCT06341036
- Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03862157Phase 1/21 country
- A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentActive, not recruitingNCT04576156Phase 326 countries
- To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)CompletedNCT04629508Phase 27 countries
- A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ETActive, not recruitingNCT05482971Phase 22 countries
- A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia PatientsActive, not recruitingNCT06514807Phase 310 countries
- Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring SideroblastsTerminatedNCT05005182Phase 21 country
- A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsTerminatedNCT04637009Phase 12 countries
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 11 country
- Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative NeoplasiaActive, not recruitingNCT062460061 country
- Elevated Platelet Count as Prognostic Factor in Colorectal Cancer With Synchronous Liver MetastasesCompletedNCT037175191 country
- A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial TherapyWithdrawnNCT04354727Phase 1/21 country
- Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT01998828Phase 25 countries
- A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFCompletedNCT01787552Phase 1/211 countries
- Pomalidomide for Myelofibrosis PatientsCompletedNCT00946270Phase 21 country
- Platelets Count Alterations in Patients With Acute Coronary SyndromeCompletedNCT035834111 country
- Predictors of Reactive Thrombocytosis in Critically Ill Septic PatientsStatus unknownNCT035315151 country
- Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisCompletedNCT00509899Phase 1/21 country
- Decitabine for High-Risk Sickle Cell DiseaseCompletedNCT01375608Phase 21 country
- A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow DisordersCompletedNCT02125318Phase 21 country
- Primary Thrombocythaemia 1 TrialCompletedNCT00175838Not applicable1 country
- Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia MyelofibrosisWithdrawnNCT02805868Early Phase 1
- Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet DepletionsCompletedNCT023087872 countries
- Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)CompletedNCT01558739Phase 41 country
- The Spleen in Sickle Cell Anemia and Sickle Cell ThalassemiaCompletedNCT009716981 country
- The Role of Reactive Thrombocytosis in Children With Pneumococcal InfectionCompletedNCT011943491 country
- Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)TerminatedNCT00882414Phase 21 country